Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imetelstat - Geron Corporation

Drug Profile

Imetelstat - Geron Corporation

Alternative Names: GRN 140719; GRN 163; GRN 163-L; GRN 719; GRN163L peptide; Imetelstat sodium; JNJ-63935937

Latest Information Update: 07 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geron Corporation
  • Developer Geron Corporation; Janssen Biotech
  • Class Antifibrotics; Antineoplastics; Oligonucleotides; Oligopeptides
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelodysplastic syndromes
  • Phase II Myelofibrosis
  • Preclinical Chronic myeloid leukaemia
  • Suspended Multiple myeloma
  • No development reported Acute myeloid leukaemia
  • Discontinued Breast cancer; Essential thrombocythaemia; Lymphoproliferative disorders; Non-small cell lung cancer; Polycythaemia vera; Solid tumours

Most Recent Events

  • 30 Sep 2019 Imetelstat receives Fast Track designation for Myelofibrosis (Primary and secondary) [IV,Infusion] in USA
  • 08 Aug 2019 Phase-III clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in United Kingdom, Italy, Russia, Germany, South Korea, Belgium, France, Spain, Netherlands, USA (IV)
  • 15 Jun 2019 Adverse events and efficacy data from the phase II IMbark trial in Myelofibrosis presented at the European Hematology Association (EHA-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top